Premium
The use of selective progestin receptor modulators ( SPRMs ) and more specifically ulipristal acetate in the practice of gynaecology
Author(s) -
Rozenberg Serge,
Praet Julie,
Pazzaglia Eliza,
Gilles Christine,
Manigart Yannick,
Vandromme Jean
Publication year - 2017
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/ajo.12641
Subject(s) - ulipristal acetate , progestin , receptor , medicine , pharmacology , chemistry , gynecology , hormone , research methodology , family planning , population , environmental health
This review discusses the development of selective progestin receptor modulators ( SPRMs ) for use in women's health and specifically the use of ulipristal acetate ( UPA ) as emergency contraception ( EC ) and as a treatment for symptomatic fibroids in women who want to preserve their fertility or avoid a hysterectomy. As an EC , UPA 30 mg should be recommended for women, within 102 h of unprotected intercourse. As a treatment of fibroids, UPA (5 mg daily dose) should be administered for periods of three months as a pre‐surgical strategy, reducing bleeding and fibroid size and facilitating surgery. A proportion of these patients may even avoid surgery. Future developments will demonstrate whether UPA can be used for other indications such as endometriosis and breast cancer prevention or treatment.